Head-to-head · Cost-Efficiency Index
Ondra Health vs Ro
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Ondra Health
Value shoppers who want one of the lowest disclosed prices on both molecules without giving up nationwide access or pharmacy verification.
Visit Ondra HealthRo
People who need brand-name (Wegovy/Zepbound) access or insurance navigation and will accept price opacity for it.
Visit RoThe verdict
Ondra Health takes it, leading the Cost-Efficiency Index 90 to 84. A rare combination — near-rock-bottom pricing on both molecules, all-50 access, brand-name availability, and a LegitScript-verified pharmacy behind it. Ro still earns a B — People who need brand-name (Wegovy/Zepbound) access or insurance navigation and will accept price opacity for it.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the board). See how it stacks up: CoreAge Rx vs Ondra Health.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Ondra Health | Ro |
|---|---|---|
| Cost-Efficiency Index | 90/100 | 84/100 |
| Semaglutide / mo | $93/mo | Not disclosed |
| Tirzepatide / mo | $166/mo | Not disclosed |
| Semaglutide / yr (modeled) | $1,116 | — |
| Tirzepatide / yr (modeled) | $1,992 | — |
| Coverage | All 50 states | Multi-state |
| Oral / sublingual | No | Yes |
| Brand-name access | Yes | Yes |
| Rank on the board | #2 | #19 |
Ondra Health
90/100Where the value is
- Among the lowest disclosed prices on the board — $93 semaglutide and $166 tirzepatide
- Available in all 50 states with both molecules published for clean cost modeling
- LegitScript-certified, and offers FDA-approved brand-name access alongside compounded
The tradeoffs
- A newer, lower-profile operator without CoreAge's long flat-price track record
- No oral/sublingual route
Ro
84/100Where the value is
- Brand-name access and insurance support
- Oral options widen the formulary
- Polished, well-funded platform
The tradeoffs
- Does not publish compounded pricing up front — a blind spot in any cost model
- Premium positioning
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.